Summit Healthcare Acquisition Corp. (SMIH) to Combine with YS Biopharma in $1Bn Deal
Summit (NASDAQ:SMIH) has entered into a definitive agreement to combine with drug-maker YS Biopharma at an enterprise value of $1.08 billion, or about 15.2x its 2022E revenue. The Beijing-based company currently makes a rabies vaccine for the Chinese market and is working to commercialize a range of new vaccines and other treatments. The combined companyRead More
To access this post, you must purchase 1 - User: Monthly Plan.